Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
444 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00373529 | A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II) | completed | Phase 2 | 116 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 14, 2014 | clinicaltrials |
| NCT00044889 | Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00125827 | Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors | completed | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00356460 | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma | completed | Phase 1 | 29 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00942799 | Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors | completed | Phase 1 | 87 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT01090167 | A Study of Clofarabine in Japanese Patients With Acute Myeloid Leukemia (AML) | completed | Phase 1 | 14 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT01196013 | A Study of Clofarabine in Japanese Paediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukaemia | completed | Phase 1 | 7 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00086580 | Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients | completed | Phase 3 | 335 | Genzyme, a Sanofi CompanyINDUSTRY | 15 | Mar 13, 2014 | clinicaltrials |
| NCT00103610 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients | completed | Phase 3 | 298 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Mar 13, 2014 | clinicaltrials |
| NCT00103662 | Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients | completed | Phase 3 | 302 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Mar 13, 2014 | clinicaltrials |
| NCT00322387 | Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322491 | Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 49 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00322842 | Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients | completed | Phase 2 | 35 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00328198 | Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 86 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Mar 13, 2014 | clinicaltrials |
| NCT00396201 | AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00396331 | AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts | completed | Phase 2 | 100 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00396383 | Treatment With AMD3100 (Plerixafor) in MM Patients to Mobilize PBCs For Collection and for Transplantation | terminated | Phase 2 | 9 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00444912 | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT00396266 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 7, 2014 | clinicaltrials |
| NCT01038661 | Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy(TFINE) | completed | Phase 3 | 375 | SanofiINDUSTRY | 1 | Feb 28, 2014 | clinicaltrials |
| NCT01164475 | Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms | completed | Phase 4 | 61 | Genzyme, a Sanofi CompanyINDUSTRY | 4 | Feb 25, 2014 | clinicaltrials |
| NCT00396968 | AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS | withdrawn | Phase 1 / Phase 2 | 0 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00741325 | Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610). | completed | — | 178 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Feb 11, 2014 | clinicaltrials |
| NCT00930098 | A Phase II, Open-Label Study of Clofarabine in Paediatric Patients With Refractory/Relapsed Acute Lymphoblastic Leukaemia | completed | Phase 2 | 74 | Genzyme, a Sanofi CompanyINDUSTRY | 6 | Feb 11, 2014 | clinicaltrials |
| NCT00113048 | Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies | terminated | Phase 1 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT00125840 | Clofarabine in Adult Patients With Advanced Solid Tumors | completed | Phase 1 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 5, 2014 | clinicaltrials |
| NCT01045304 | Study of SAR240550 (BSI-201) in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer | completed | Phase 2 | 163 | SanofiINDUSTRY | 6 | Jan 14, 2014 | clinicaltrials |
| NCT00003305 | Aminopterin in Treating Patients With Refractory Leukemia | completed | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00004025 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00008281 | Comparison of Three Chemotherapy Regimens in Treating Patients With Metastatic Colorectal Cancer | unknown | Phase 3 | — | SanofiINDUSTRY | 2 | Jan 6, 2014 | clinicaltrials |
| NCT00010309 | Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00312208 | Docetaxel in Breast Cancer | completed | Phase 3 | 3,299 | SanofiINDUSTRY | 37 | Dec 30, 2013 | clinicaltrials |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma(PREMIER) | terminated | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Dec 27, 2013 | clinicaltrials |
| NCT00012389 | Irinotecan With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 3 | — | SanofiINDUSTRY | 7 | Dec 19, 2013 | clinicaltrials |
| NCT00185445 | Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL | completed | Phase 2 | 62 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00220311 | A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia | completed | Phase 4 | 10 | Genzyme, a Sanofi CompanyINDUSTRY | 0 | Dec 4, 2013 | clinicaltrials |
| NCT00311129 | Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHL | completed | Phase 2 | 41 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00344825 | Vitalis Study - Observational Study on the Quality of Life in Patients Under Treatment for B-Chronic Lymphocytic Leukemia (B-CLL) | completed | — | 300 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00688883 | Fludara (Oral) Phase II Study for Indolent Lymphoma | completed | Phase 2 | 52 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT01527929 | Pharmacokinetics and Safety Study of Cabazitaxel in Cancer Patients With Renal Impairment | completed | Phase 1 | 25 | SanofiINDUSTRY | 5 | Dec 4, 2013 | clinicaltrials |
| NCT00181597 | Trilostane for Androgen-Independent Prostate Cancer | completed | Phase 2 | 24 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 3, 2013 | clinicaltrials |
| NCT00836043 | Safety, Effectiveness and Patient Acceptance of the Treatment With MabCampath in Chronic Lymphocytic Leukemia | terminated | — | 6 | Genzyme, a Sanofi CompanyINDUSTRY | 3 | Dec 3, 2013 | clinicaltrials |
| NCT00514917 | A Study of Androgen Deprivation With Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Participants With a Rising Prostate Specific Antigen (PSA)(Rising PSA) | terminated | Phase 3 | 413 | SanofiINDUSTRY | 9 | Nov 4, 2013 | clinicaltrials |
| NCT00545246 | A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer Patients | completed | Phase 1 | 12 | SanofiINDUSTRY | 1 | Oct 16, 2013 | clinicaltrials |
| NCT01095302 | Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients With Solid Tumors | completed | Phase 1 | 11 | SanofiINDUSTRY | 1 | Oct 16, 2013 | clinicaltrials |
| NCT00677079 | Single Arm Study of BSI-201 in Patients With BRCA-1 or BRCA-2 Associated Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 12 | SanofiINDUSTRY | 1 | Oct 1, 2013 | clinicaltrials |
| NCT01086254 | SAR240550 in Combination With Gemcitabine/Cisplatin in Non-small Cell Lung Cancer | completed | Phase 2 | 119 | SanofiINDUSTRY | 5 | Sep 24, 2013 | clinicaltrials |
| NCT01161836 | An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi) | completed | Phase 1 | 7 | SanofiINDUSTRY | 1 | Sep 24, 2013 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials